Logotype for Astellas Pharma Inc

Astellas Pharma (4503) Q2 2027 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Astellas Pharma Inc

Q2 2027 earnings summary

11 Nov, 2026

Executive summary

  • H1 revenue rose 23.4% YoY to ¥1,270.9bn; core operating profit increased 50.3% to ¥424.9bn, supported by Strategic Brands, cost discipline and favorable FX.

  • FY2026 guidance was raised; pipeline advances included two Phase 3 first-subject-dosed milestones, ASP6958 proof of concept in mCRPC and three new clinical-stage programs.

Financial highlights

  • Reported operating profit was ¥316.6bn, up 58.8% YoY; profit was ¥241.5bn, up 63.6%.

  • Core profit increased 56.8% to ¥331.5bn; basic core EPS rose 56.7% to ¥185.02.

  • Gross profit increased 23.3% to ¥1,023.0bn; SG&A rose 6.6% to ¥430.4bn and R&D expenses rose 17.0% to ¥167.7bn.

  • Strategic Brands sales reached ¥333.9bn, up 51.4%; XTANDI sales were ¥533.7bn, up 11.9%, with favorable FX contributing.

  • ASP5541 development was discontinued, resulting in a ¥26.4bn impairment loss.

Outlook and guidance

  • FY2026 revenue forecast rose ¥110bn to ¥2,330bn; core operating profit guidance increased ¥80bn to ¥700bn, targeting a 30.0% margin.

  • Full-basis operating profit forecast increased ¥65bn to ¥460bn; profit before tax is forecast at ¥450bn and profit at ¥350bn.

  • Core profit guidance rose ¥60bn to ¥520bn; basic core EPS forecast is ¥290.04.

  • Strategic Brands sales guidance increased to ¥680bn; XTANDI is expected to decline in 2H due to the US IRA impact, while PADCEV outlook increased.

  • Forecast FX assumptions are ¥158/US$ and ¥181/€; Q3 onward assumptions are ¥156/US$ and ¥177/€.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Astellas Pharma